3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
95
Myelodysplastic Syndromes
26
Recurrence
25
Lymphoma, Non-Hodgkin
24
Neoplasms
21
Leukemia, Lymphocytic, Chronic, B-Cell
19
Lymphoma, Large B-Cell, Diffuse
15
Leukemia
12
Lymphoma, Follicular
10
Multiple Myeloma
9
Hematologic Neoplasms
9
Lymphoma, B-Cell, Marginal Zone
8
Burkitt Lymphoma
7
Lymphoma, Mantle-Cell
6
Lymphoma, B-Cell
6
Lymphoma
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasm Metastasis
4
Myeloproliferative Disorders
4
Leukemia, Biphenotypic, Acute
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
GATA2 Deficiency
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Primary Myelofibrosis
2
Immunoglobulin Light-chain Amyloidosis
2
Colorectal Neoplasms
2
Interventions
Cyclophosphamide
12
fludarabine
10
fludarabine phosphate
7
Radiotherapy
6
Mycophenolic Acid
6
Whole-Body Irradiation
5
Sirolimus
5
Filgrastim
5
Tacrolimus
4
Melphalan
4
Busulfan
4
Peripheral Blood Stem Cell Transplantation
3
Methylprednisolone
3
Cyclosporine
3
Thiotepa
2
Stem Cell Transplantation
2
Specimen Handling
2
Rituximab
2
Methotrexate
2
Mesna
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
venetoclax
1
siplizumab
1
rasburicase
1
prostaglandin D2 receptor
1
milatuzumab
1
itacitinib
1
eritoran
1
Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Graft vs Host Disease
×
venetoclax
×
Clear all
NCT05005299
2023-08-01
VICTORY
Melbourne Health
Phase 1
Unknown
18 enrolled